Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Neut-X can be successfully used as diagnostic and prognostic tool in MDS.

Boquoi A, Barthuber C, Strapatsas J, Kuendgen A, Kobbe G, Fenk R, Gattermann N, Haas R, Germing U.

Leuk Res. 2019 Nov;86:106224. doi: 10.1016/j.leukres.2019.106224. Epub 2019 Sep 13. No abstract available.

PMID:
31586853
2.

Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, Reményi P, Blaise D, Schaap N, Trneny M, Passweg J, Porras RP, Cahn JY, Musso M, Poiré X, Fenk R, Itälä-Remes M, Pavone V, Fouillard L, Maertens J, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N.

Biol Blood Marrow Transplant. 2019 Jul 6. pii: S1083-8791(19)30436-7. doi: 10.1016/j.bbmt.2019.07.004. [Epub ahead of print]

PMID:
31288095
3.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, Blau IW, Raab MS, Hillengass J, Hose D, Huhn S, Hundemer M, Andrulis M, Jauch A, Seidel-Glaetzer A, Lindemann HW, Hensel M, Fronhoffs S, Martens U, Hansen T, Wattad M, Graeven U, Munder M, Fenk R, Haenel M, Scheid C, Goldschmidt H.

BMC Cancer. 2019 May 28;19(1):504. doi: 10.1186/s12885-019-5600-x.

4.

Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies.

Schuler E, Boughoufala S, Rautenberg C, Nachtkamp K, Dienst A, Fenk R, Haas R, Kondakci M, Germing U, Schroeder T, Kobbe G.

Ann Hematol. 2019 May;98(5):1225-1235. doi: 10.1007/s00277-019-03670-6. Epub 2019 Mar 29.

PMID:
30923997
5.

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.

Kriegsmann K, Baertsch MA, Awwad MHS, Merz M, Hose D, Seckinger A, Jauch A, Becker N, Benner A, Raab MS, Hillengass J, Bertsch U, Dürig J, Salwender HJ, Hänel M, Fenk R, Munder M, Weisel K, Müller-Tidow C, Goldschmidt H, Hundemer M.

Blood Cancer J. 2019 Jan 29;9(2):13. doi: 10.1038/s41408-019-0174-z.

6.

Interaction of increasing ICU survival and admittance policies in patients with hematologic neoplasms: A single center experience with 304 patients.

Kondakci M, Reinbach MC, Germing U, Kobbe G, Fenk R, Schroeder T, Quader J, Zeus T, Rassaf T, Haas R.

Eur J Haematol. 2019 Mar;102(3):265-274. doi: 10.1111/ejh.13206. Epub 2019 Jan 17.

PMID:
30578742
7.

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.

Awwad MHS, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab MS, Bertsch U, Munder M, Weisel K, Salwender HJ, Hänel M, Fenk R, Dürig J, Müller-Tidow C, Goldschmidt H, Hundemer M.

Oncoimmunology. 2018 Aug 1;7(10):e1486356. doi: 10.1080/2162402X.2018.1486356. eCollection 2018.

8.

[2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity].

Bönner F, Fenk R, Kochanek M, Pfister R.

Dtsch Med Wochenschr. 2017 Dec;142(24):1826-1830. doi: 10.1055/s-0043-112775. Epub 2017 Dec 5. German.

PMID:
29207427
9.

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.

Baertsch MA, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K, Noppeney R, Martin H, Lindemann HW, Haenel M, Nogai A, Scheid C, Salwender H, Fenk R, Graeven U, Reimer P, Schmidt-Hieber M, Goerner M, Schmidt-Wolf IGH, Klein S, Ho AD, Goldschmidt H, Wuchter P.

Eur J Haematol. 2017 Jul;99(1):42-50. doi: 10.1111/ejh.12888. Epub 2017 May 24.

PMID:
28370401
10.

Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis.

Wilk CM, Heinzler N, Boquoi A, Cadeddu RP, Strapatsas T, Dienst A, Majidi F, Deenen R, Bruns I, Schroeder T, Köhrer K, Haas R, Kobbe G, Fenk R.

Int J Cancer. 2016 Nov 15;139(10):2343-52. doi: 10.1002/ijc.30257. Epub 2016 Aug 13.

11.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengaß J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H.

BMC Cancer. 2016 Apr 25;16:290. doi: 10.1186/s12885-016-2321-2.

12.

Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia.

Geyh S, Rodríguez-Paredes M, Jäger P, Khandanpour C, Cadeddu RP, Gutekunst J, Wilk CM, Fenk R, Zilkens C, Hermsen D, Germing U, Kobbe G, Lyko F, Haas R, Schroeder T.

Leukemia. 2016 Mar;30(3):683-91. doi: 10.1038/leu.2015.325. Epub 2015 Nov 25.

PMID:
26601782
13.

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.

Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, Maschmeyer G, Kofahl-Krause D, Niederle N, Heil G, Losem C, Welslau M, Brugger W, Germing U, Kronenwett R, Barth J, Rummel MJ, Haas R, Kobbe G.

Blood. 2015 Sep 17;126(12):1407-14. doi: 10.1182/blood-2015-03-630012. Epub 2015 Aug 3.

PMID:
26239087
14.

Reply to 'allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome'.

Schroeder T, Fenk R, Haas R, Germing U, Kobbe G.

Bone Marrow Transplant. 2015 Nov;50(11):1483-5. doi: 10.1038/bmt.2015.176. Epub 2015 Aug 3. No abstract available.

PMID:
26237167
15.

Effects of Radiotherapy in the treatment of multiple myeloma: a retrospective analysis of a Single Institution.

Matuschek C, Ochtrop TA, Bölke E, Ganswindt U, Fenk R, Gripp S, Kröpil P, Gerber PA, Kammers K, Hamilton J, Orth K, Budach W.

Radiat Oncol. 2015 Mar 28;10:71. doi: 10.1186/s13014-015-0374-z.

16.

Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.

Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK, Wolf D, Ringhoffer M, Czibere A, Nachtkamp K, Dienst A, Kondakci M, Stadler M, Platzbecker U, Uharek L, Luft T, Fenk R, Germing U, Bornhäuser M, Kröger N, Beelen DW, Haas R, Kobbe G.

Biol Blood Marrow Transplant. 2015 Apr;21(4):653-60. doi: 10.1016/j.bbmt.2014.12.016. Epub 2014 Dec 23.

17.

Primary cardiac sarcoma: a rare disease with rapid progression.

Bönner F, Haberkorn SM, Fenk R, Kelm M, Balzer J.

Eur Heart J. 2015 Mar 14;36(11):698. doi: 10.1093/eurheartj/ehu431. Epub 2014 Dec 10. No abstract available.

PMID:
25538091
18.

Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.

Geyh S, Oz S, Cadeddu RP, Fröbel J, Brückner B, Kündgen A, Fenk R, Bruns I, Zilkens C, Hermsen D, Gattermann N, Kobbe G, Germing U, Lyko F, Haas R, Schroeder T.

Leukemia. 2013 Sep;27(9):1841-51. doi: 10.1038/leu.2013.193. Epub 2013 Mar 29.

PMID:
23797473
19.

Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.

Korthals M, Sehnke N, Kronenwett R, Schroeder T, Strapatsas T, Kobbe G, Haas R, Fenk R.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1109-15. doi: 10.1016/j.bbmt.2013.04.025. Epub 2013 May 2.

20.

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.

Schroeder T, Fröbel J, Cadeddu RP, Czibere A, Dienst A, Platzbecker U, Bug G, Uharek L, Fenk R, Germing U, Kröger N, Haas R, Kobbe G.

Leukemia. 2013 Sep;27(9):1910-3. doi: 10.1038/leu.2013.64. Epub 2013 Mar 1. No abstract available.

PMID:
23519388
21.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G.

Leukemia. 2013 Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14.

PMID:
23314834
22.

Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells.

Bruns I, Cadeddu RP, Brueckmann I, Fröbel J, Geyh S, Büst S, Fischer JC, Roels F, Wilk CM, Schildberg FA, Hünerlitürkoglu AN, Zilkens C, Jäger M, Steidl U, Zohren F, Fenk R, Kobbe G, Brors B, Czibere A, Schroeder T, Trumpp A, Haas R.

Blood. 2012 Sep 27;120(13):2620-30. Epub 2012 Apr 18.

23.

Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation.

Fenk R, Neubauer F, Bruns I, Schröder T, Germing U, Haas R, Kobbe G.

Br J Haematol. 2012 Mar;156(5):683-6. doi: 10.1111/j.1365-2141.2011.08905.x. Epub 2011 Nov 3. No abstract available.

PMID:
22050384
24.

Therapy-related myeloid neoplasms following treatment with radioiodine.

Schroeder T, Kuendgen A, Kayser S, Kröger N, Braulke F, Platzbecker U, Klärner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere AG, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U.

Haematologica. 2012 Feb;97(2):206-12. doi: 10.3324/haematol.2011.049114. Epub 2011 Oct 11.

25.

Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.

Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G.

Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29.

26.

The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.

Korthals M, Sehnke N, Kronenwett R, Bruns I, Mau J, Zohren F, Haas R, Kobbe G, Fenk R.

Biol Blood Marrow Transplant. 2012 Mar;18(3):423-431.e3. doi: 10.1016/j.bbmt.2011.07.002. Epub 2011 Jul 13.

27.

Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.

Fenk R, Liese V, Neubauer F, Bruns I, Kondakci M, Balleisen S, Saure C, Schröder T, Haas R, Kobbe G.

Leuk Lymphoma. 2011 Aug;52(8):1455-62. doi: 10.3109/10428194.2011.575967. Epub 2011 Jun 10.

PMID:
21657961
28.

High-dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma.

Haas R, Bruns I, Kobbe G, Fenk R.

Recent Results Cancer Res. 2011;183:207-38. doi: 10.1007/978-3-540-85772-3_10. Review.

PMID:
21509687
29.

Increased numbers of tumor-lysing monocytes in cancer patients.

Papewalis C, Jacobs B, Baran AM, Ehlers M, Stoecklein NH, Willenberg HS, Schinner S, Anlauf M, Raffel A, Cupisti K, Fenk R, Scherbaum WA, Schott M.

Mol Cell Endocrinol. 2011 Apr 30;337(1-2):52-61. doi: 10.1016/j.mce.2011.01.020. Epub 2011 Feb 1.

PMID:
21291954
30.

Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.

Schroeder T, Zohren F, Saure C, Bruns I, Czibere A, Safaian NN, Fenk R, Haas R, Kobbe G.

Acta Haematol. 2010;124(3):153-9. doi: 10.1159/000320173. Epub 2010 Oct 11. No abstract available.

PMID:
20938170
31.

Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.

Zohren F, Schroeder T, Czibere A, Fenk R, Bruns I, Kondakci M, Saure C, Haas R, Kobbe G.

Bone Marrow Transplant. 2011 May;46(5):747-55. doi: 10.1038/bmt.2010.167. Epub 2010 Jul 26.

PMID:
20661230
32.

The Mexican way: a feasible approach to avoid DMSO toxicity.

Schroeder T, Fenk R, Saure C, Czibere A, Bruns I, Zohren F, Haas R, Kobbe G.

Bone Marrow Transplant. 2011 Mar;46(3):469-71. doi: 10.1038/bmt.2010.140. Epub 2010 Jun 14. No abstract available.

PMID:
20548338
33.

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma.

Kobbe G, Bruns I, Schroeder T, Czibere A, Warnecke J, Hieronimus N, Safaian N, Kondakci M, Saure C, Germing U, Haas R, Fenk R.

Ann Oncol. 2010 Sep;21(9):1898-904. doi: 10.1093/annonc/mdq059. Epub 2010 Mar 16.

PMID:
20233744
34.

Bendamustine in patients with relapsed or refractory multiple myeloma.

Michael M, Bruns I, Bölke E, Zohren F, Czibere A, Safaian NN, Neumann F, Haas R, Kobbe G, Fenk R.

Eur J Med Res. 2010 Jan 29;15(1):13-9.

35.

Bortezomib induces erythema multiforme-like cutaneous adverse effects: report of two cases.

Gerber PA, Bölke E, Buhren BA, Bruch-Gerharz D, Fenk R, Reifenberger J, Budach W, Haas R, Homey B.

Wien Klin Wochenschr. 2009;121(21-22):723-4. doi: 10.1007/s00508-009-1267-7. No abstract available.

PMID:
19998015
36.

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.

Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schröder T, Gräf T, Haas R, Kobbe G.

Bone Marrow Transplant. 2010 May;45(5):872-6. doi: 10.1038/bmt.2009.266. Epub 2009 Oct 12.

PMID:
19820729
37.

Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.

Zohren F, Czibere A, Bruns I, Fenk R, Schroeder T, Gräf T, Haas R, Kobbe G.

Bone Marrow Transplant. 2009 Dec;44(12):785-92. doi: 10.1038/bmt.2009.83. Epub 2009 May 11.

PMID:
19430496
38.

Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT.

Kobbe G, Bruns I, Fenk R, Czibere A, Haas R.

Bone Marrow Transplant. 2009 May;43(9):669-77. doi: 10.1038/bmt.2009.59. Epub 2009 Mar 23. Review.

PMID:
19308043
39.

[Radiotherapy of soft tissue sarcoma--part of a multidisciplinary strategy].

Pape H, Orth K, Engers R, Matuschek C, Müller A, Hartmann KA, Gerber PA, Lammering G, Habermehl D, Fenk R, Budach W, Gripp S, Peiper M, Bölke E.

Wien Klin Wochenschr. 2008;120(23-24):723-31. doi: 10.1007/s00508-008-1115-1. Review. German.

PMID:
19122982
40.

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.

Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A, Haas R, Kobbe G.

Leuk Res. 2009 Feb;33(2):348-50. doi: 10.1016/j.leukres.2008.04.017. Epub 2008 Jun 24.

PMID:
18573526
41.

Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study.

Neumann F, Markett J, Fenk R, Pooten M, Koch A, Bruennert D, Schimkus N, Wulfert M, Royer-Pokora B, Kronenwett R, Haas R, Gattermann N.

Hematol Oncol. 2008 Dec;26(4):213-8. doi: 10.1002/hon.860.

PMID:
18449950
42.

Characterization of monocyte-derived IFNalpha-generated dendritic cells.

Jacobs B, Wuttke M, Papewalis C, Fenk R, Stüssgen C, Baehring T, Schinner S, Raffel A, Seissler J, Schott M.

Horm Metab Res. 2008 Feb;40(2):117-21. doi: 10.1055/s-2007-1022564.

PMID:
18283629
43.

Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.

Papewalis C, Wuttke M, Jacobs B, Domberg J, Willenberg H, Baehring T, Cupisti K, Raffel A, Chao L, Fenk R, Seissler J, Scherbaum WA, Schott M.

Horm Metab Res. 2008 Feb;40(2):108-16. doi: 10.1055/s-2007-1022565.

PMID:
18283628
44.

Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.

Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S, Singh R, Fenk R, Rosskopf M, Pechtel S, von Haeseler A, Wernet P, Tenen DG, Haas R, Kronenwett R.

Haematologica. 2008 Mar;93(3):347-55. doi: 10.3324/haematol.12081. Epub 2008 Feb 11.

45.

Unrelated umbilical cord blood transplantation as salvage treatment for engraftment failure following autologous stem cell transplantation.

Fenk R, Neumann F, Fenk B, Ruf L, Zohren F, Safaian NN, Haas R, Kobbe G.

Leuk Res. 2008 Jul;32(7):1157-9. doi: 10.1016/j.leukres.2007.12.003. Epub 2008 Jan 25.

PMID:
18221996
46.

The sepsis-related Organ Failure Assessment (SOFA) score is predictive for survival of patients admitted to the intensive care unit following allogeneic blood stem cell transplantation.

Neumann F, Lobitz O, Fenk R, Bruns I, Köstering M, Steiner S, Hennersdorf M, Kelm M, Strauer BE, Germing U, Hinke A, Haas R, Kobbe G.

Ann Hematol. 2008 Apr;87(4):299-304. doi: 10.1007/s00277-008-0440-9. Epub 2008 Jan 25.

PMID:
18219487
47.

IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo.

Papewalis C, Jacobs B, Wuttke M, Ullrich E, Baehring T, Fenk R, Willenberg HS, Schinner S, Cohnen M, Seissler J, Zacharowski K, Scherbaum WA, Schott M.

J Immunol. 2008 Feb 1;180(3):1462-70.

48.

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.

Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, Neumann F, Fenk B, Haas R, Kobbe G.

Leuk Lymphoma. 2007 Dec;48(12):2345-51.

PMID:
18067009
49.

Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma.

Kröpil P, Fenk R, Fritz LB, Blondin D, Kobbe G, Mödder U, Cohnen M.

Eur Radiol. 2008 Jan;18(1):51-8. Epub 2007 Oct 9.

PMID:
17924119
50.

Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis.

Korthals M, Safaian N, Kronenwett R, Maihöfer D, Schott M, Papewalis C, Diaz Blanco E, Winter M, Czibere A, Haas R, Kobbe G, Fenk R.

J Transl Med. 2007 Sep 25;5:46.

Supplemental Content

Support Center